Add-back capsule (E2 1 mg / NETA 0.5 mg)

DRUG4 trials

Sponsors

Kissei Pharmaceutical Co., Ltd.

Conditions

Endometriosis

Phase 3

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

TerminatedNCT03986944

Kissei Pharmaceutical Co., Ltd.Endometriosis

Start: 2019-05-23End: 2021-02-16Updated: 2025-04-02

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

CompletedNCT03992846

Kissei Pharmaceutical Co., Ltd.Endometriosis

Start: 2019-06-13End: 2022-04-01Updated: 2025-04-02

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

CompletedNCT04335591

Kissei Pharmaceutical Co., Ltd.Endometriosis

Start: 2020-03-05End: 2022-12-15Updated: 2025-04-02

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

TerminatedNCT04372121

Kissei Pharmaceutical Co., Ltd.Endometriosis

Start: 2020-03-23End: 2021-02-16Updated: 2025-04-02

Related Papers

O-269 Long term efficacy of Linzagolix in women with endometriosis-associated pain

Human Reproduction2024-07-01

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).

2024-06-0117 citations

O-027 Efficacy results from a phase 3, randomized, placebo-controlled trial testing two doses of linzagolix in women with endometriosis-associated pain

Human Reproduction2023-06-011 citations

O-306 LINZAGOLIX FOR ENDOMETRIOSIS-ASSOCIATED PAIN: SAFETY RESULTS FROM EDELWEISS 3, A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Human Reproduction2022-06-291 citations